The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

The notion that we should require placebo trials even when there's already a safe, effective vaccine goes against decades of ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

Health News // 5 days ago After 2 reported deaths, officials tell Ixchiq users age 60+ to stop vaccine temporarily May 12 (UPI) -- The Trump administration's FDA and CDC is advising U.S. patients ...

May 12 (UPI) -- The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults ...